Abstract: SA-PO0864
Efficacy and Safety Evaluation of Telitacicept in IgAN
Session Information
- Glomerular Management: Real-World Lessons and Emerging Therapies
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Yang, Yan, Zhongshan Hospital Fudan University, Shanghai, China
- Jin, Shi, Zhongshan Hospital Fudan University, Shanghai, China
- Shi, Yiqin, Zhongshan Hospital Fudan University, Shanghai, China
Background
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Telitacicept is a dual-target fusion protein that inhibits both BAFF and APRIL. This study explored the efficacy and safety of telitacicept in adult IgAN.
Methods
We included biopsy-proven IgAN patients who received telitacicept treatment. The primary outcomes were the change in 24-hour proteinuria and eGFR over time.
Results
A total of 62 patients were recruited. The 24-hour proteinuria reduced significantly from 2.25 (1.26, 3.16) g to 0.42 (0.26, 1.00) g at 6-month-follow-up. The level of eGFR remained stable (57 [37, 75] vs 59 [48.5, 90] mL/min/1.73m2). The patients were then divided into the glucocorticoids (GC) combined group (C group, n=45) and telitacicept alone group (A group, n=17). The baseline proteinuria level in C group was higher (2.39 g vs 1.62 g). There was a notable decrease of proteinuria at 1 month compared with baseline in C group, while the decrease was observed at 3 months in A group. No serious adverse events were recorded.
Conclusion
Telitacicept may be an effective and safe treatment for IgAN. The combination of GC could reduce proteinuria more quickly.
Fig. 1 Changes in proteinuria and eGFR levels during follow up. Data are expressed as median and interquartile ranges. *p<0.05.
Fig. 2 Changes in proteinuria in two subgroups during follow up. Data are expressed as median and interquartile ranges. *p<0.05. A. Patients treated with telitacicept plus glucocorticoid (C group). B. Patients treated with telitacicept alone (A group).